Kinin receptors as targets for cancer therapy

Expert Opinion on Therapeutic Targets
Carlos D FigueroaKanti D Bhoola

Abstract

Biological fluids of cancer patients contain increased levels of kinins. Activation of kinin B1 and B2 receptors expressed on cancer cells produce an increase in cell proliferation, migration of tumor cells and release of MMPs, which are cellular and molecular events of primary importance for tumor growth. The effects of kinins on tumor cells may be amplified by stimulation of kinin receptors expressed on other cells, within the tumor microenvironment, which may in turn increase tumor growth. This review provides a comprehensive discourse on kinins and their receptors in human neoplasia. Concepts that view kinin receptors as targets for human cancer are explored, whilst the molecular basis by which the new dimerized kinin receptor antagonists produce arrest of cell proliferation and apoptosis of cancer cells is also examined. Finally, the role of kinin receptor antagonists as therapeutic tools against human neoplasia is analyzed. At the present time the available potent, dimerized kinin peptide antagonists, are either specific for B1 or B2 receptors, or are effective on both receptor types. The novel approach of using kinin receptor antagonists either alone or in combination therapy will play a definitive role in the treatment ...Continue Reading

References

Mar 1, 1991·British Journal of Pharmacology·F J HockJ Knolle
Aug 19, 1992·International Journal of Cancer. Journal International Du Cancer·H B Bueno de MesquitaA M Walker
Mar 1, 1991·Journal of Medicinal Chemistry·D J KyleR M Burch
Jun 1, 1991·Japanese Journal of Cancer Research : Gann·Y MatsumuraH Maeda
Dec 1, 1988·Japanese Journal of Cancer Research : Gann·Y MatsumuraH Maeda
Jan 1, 1986·Advances in Experimental Medicine and Biology·J M Stewart, R J Vavrek
Mar 1, 1985·Peptides·R J Vavrek, J M Stewart
Apr 1, 1970·Proceedings of the Society for Experimental Biology and Medicine·J F WhitfieldD J Gillan
Jun 1, 1995·Immunopharmacology·F Marceau
Jan 1, 1995·Journal of Cancer Research and Clinical Oncology·J RehbockC Figueroa
Jun 1, 1996·Immunopharmacology·L GeraJ S Zuzack
Jun 1, 1996·Immunopharmacology·H MaedaY Sakata
Dec 22, 1999·Immunopharmacology·H MaedaT Akaike
Dec 22, 1999·Immunopharmacology·D M RaidooK D Bhoola
Jun 1, 2000·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·D J Campbell
Jun 23, 2000·Pain·J B CalixtoM M Campos
Sep 22, 2000·Molecular Pharmacology·C HecquetE G Erdös
Nov 9, 2000·The Journal of Experimental Medicine·J ScharfsteinW Müller-Esterl
Mar 22, 2001·Biological Chemistry·K BhoolaS Naicker
May 24, 2001·The Journal of Urology·L Barki-Harrington, Y Daaka
Feb 15, 2002·Journal of Biomolecular Structure & Dynamics·Mark MiskolzieGeorge Kotovych
Feb 22, 2002·International Journal of Cancer. Journal International Du Cancer·Jun WuHiroshi Maeda
Apr 4, 2002·Proceedings of the National Academy of Sciences of the United States of America·Daniel ChanPaul Bunn
May 25, 2002·Canadian Journal of Physiology and Pharmacology·John M StewartBarbara Helfrich
Dec 20, 2002·International Immunopharmacology·Claudie HecquetErvin G Erdös
Jul 17, 2003·International Journal of Cancer. Journal International Du Cancer·Margaret J Slattery, Cheng Dong
Aug 15, 2003·Molecular & Cellular Proteomics : MCP·Radhakrishna S TirumalaiTimothy D Veenstra
Oct 8, 2003·Current Pharmaceutical Design·J M Stewart
Jan 22, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Giselle F PassosJoão B Calixto
Mar 23, 2004·The Journal of Biological Chemistry·Dong Soo KangL M Fredrik Leeb-Lundberg
May 12, 2004·Peptides·John M Stewart
Jul 29, 2004·Journal of Cellular Physiology·S GrecoSanto Marsigliante
Oct 2, 2004·Nature Reviews. Drug Discovery·François Marceau, Domenico Regoli

❮ Previous
Next ❯

Citations

Jan 9, 2013·Expert Opinion on Therapeutic Targets·Catherine J Denis, Anne-Marie Lambeir
Aug 21, 2013·Expert Opinion on Therapeutic Targets·Nelly Blaes, Jean-Pierre Girolami
Oct 26, 2012·Expert Opinion on Drug Discovery·Eric T WhalleyKanti D Bhoola
Dec 4, 2012·International Immunopharmacology·Caroline Sandén, L M Fredrik Leeb-Lundberg
Dec 17, 2015·Cytometry. Part a : the Journal of the International Society for Analytical Cytology·Micheli M PillatHenning Ulrich
Dec 18, 2013·Cancer Letters·Patrícia L N da CostaRoger Chammas
Nov 17, 2016·Molecular Neurobiology·Natália Fontana NicolettiFernanda Bueno Morrone
Apr 6, 2018·BMC Cancer·Patricia Luiza Nunes da CostaChristopher Christophi
Nov 24, 2017·Expert Opinion on Therapeutic Targets·Fatimunnisa Qadri, Michael Bader
Jun 10, 2018·Biological Chemistry·Carlos D FigueroaPamela Ehrenfeld
Aug 23, 2018·Journal of Cellular Physiology·Céléna DubucFernand Gobeil
Jul 25, 2014·Journal of Neuro-oncology·Natália Fontana NicolettiFernanda Bueno Morrone
Aug 11, 2021·Journal of Controlled Release : Official Journal of the Controlled Release Society·Enoch AppiahMamoru Haratake

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.